Primary mediastinal nonseminomatous germ cell tumors. A modern single institution experience

Cancer. 1990 Apr 1;65(7):1641-6. doi: 10.1002/1097-0142(19900401)65:7<1641::aid-cncr2820650731>3.0.co;2-u.

Abstract

Between 1976 and 1988, 31 patients with mediastinal nonseminomatous germ cell tumors (MNGCT) received initial cisplatin-based chemotherapy of uniform intensity. Eighteen of these patients (58%) obtained disease-free status; 11 with chemotherapy alone and seven with adjunctive surgery. Eleven have remained continuously free of disease. Two have had recurrence of teratoma and are disease-free after resection of teratoma at 12+ and 68+ months. Three patients developed recurrence of germ cell tumor. Three patients developed a hematologic malignancy. Of the 18 patients who obtained disease-free status, 15 remain alive and disease-free. Overall, 13 of the 31 patients and 24 other patients received salvage chemotherapy at Indiana University, Indianapolis, Indiana. Of these 37 patients, six obtained a disease-free status and four (11%) remain alive at 13+, 56+, 78+, and 122+ months, respectively. This series represents the largest series of patients with MNGCT ever reported. Analysis of these data and results from other recent series suggest that approximately 50% of patients with MNGCT will be cured with modern, intense cisplatin-based chemotherapy coupled with adjunctive surgery if needed.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chorionic Gonadotropin / metabolism
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Mediastinal Neoplasms / metabolism
  • Mediastinal Neoplasms / mortality
  • Mediastinal Neoplasms / therapy*
  • Neoplasms, Germ Cell and Embryonal / metabolism
  • Neoplasms, Germ Cell and Embryonal / mortality
  • Neoplasms, Germ Cell and Embryonal / secondary
  • Neoplasms, Germ Cell and Embryonal / therapy*
  • Prognosis
  • Recurrence
  • Survival Rate
  • alpha-Fetoproteins / metabolism

Substances

  • Chorionic Gonadotropin
  • alpha-Fetoproteins
  • Cisplatin